Trial Information
A Phase II Study of Combination Chemotherapy With Bevacizumab, Capecitabine and Oxaliplatin in Patients With Previously Untreated Metastatic or Recurrent Colorectal Cancer
Inclusion Criteria:
- Histologically or cytologically documented colorectal adenocarcinoma
- ECOG performance status of 2 or lower
- Adequate bone marrow function
- Adequate kidney function
- Adequate liver function
- Informed consent
Exclusion Criteria:
- Major surgical procedure or significant traumatic injury within 28 days prior to
study treatment start
- Known allergy to study drugs
Type of Study:
Interventional
Study Design:
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
time to progression
Outcome Time Frame:
6 months
Safety Issue:
No
Principal Investigator
Tae Won Kim, M.D.
Investigator Role:
Principal Investigator
Investigator Affiliation:
Asan Medical Center
Authority:
Korea: Food and Drug Administration
Study ID:
AMC-ONCGI-0277
NCT ID:
NCT00378066
Start Date:
August 2006
Completion Date:
October 2008
Related Keywords:
- Metastatic Colorectal Cancer
- Colorectal Neoplasms